Resolution Biomedical

Resolution Biomedical is a commercial-stage diagnostics and medical device company specializing in sample collection and transport systems. Its core technology is the ClearPrep liquid-based cytology platform, designed to enhance cytology specimen quality for pathology. The company successfully pivoted during the COVID-19 pandemic, developing and distributing over one million validated transport tubes for SARS-CoV-2 PCR testing, establishing a significant revenue-generating product line. RBI operates in the oncology and infectious disease diagnostics markets through a B2B model, selling to laboratories and healthcare providers.

ClearPrep liquid-based cytology system for cell collection/preservation, and proprietary formulations of specimen transport media with viral inactivation and ambient stability properties.

In liquid-based cytology, RBI competes with giants like Hologic (ThinPrep) and Becton Dickinson (SurePath). In specimen transport, it faces numerous competitors ranging from large diagnostic companies (e.g., Copan, Puritan) to many niche suppliers. Its differentiation lies in its specialized media formulation (viral inactivation, ambient stability) and proven scale during the pandemic.